Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB 100 million (USD 14.53 million) in a Series A financing round. The round was led by Harvest Capital and Fortune Capital, with participation from Zhiheng (Yantai) Entrepreneurship Service Center. The funds will be used to enhance core technology, upgrade manufacturing and operational facilities, build a stronger team, and advance industrialization efforts.
About T&L Biotechnology
Founded in 2011, T&L Biotechnology offers a range of products, including cell sorting magnetic bead reagents, eukaryotic and prokaryotic recombinant proteins, serum-free medium, cell culture kits, transfection reagents, and gene editing tool enzymes. This financing round underscores the company’s commitment to innovation and expansion in the CGT sector.-Fineline Info & Tech
